logo

For the Inventor, By the Inventor

Plymouth, MI, United States of America

Alnawaz Rehemtulla

This inventor holds 9 USPTO granted patents and 1 published patent application. Top assignees: University of Michigan, Neoplasia Press, Inc.. Active years: 2003-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Alnawaz Rehemtulla. Retrieved from https://idiyas.com/inventor/alnawaz-rehemtulla

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 

% Patents Active = 77.8

Average Co-Inventor Count = 3.4

ph-index = 6

Forward Citations = 170(Granted Patents)


Company Filing History:

goldMedal7 out of 3,543 
 
University of Michigan
 patents
silverMedal2 out of 2 
 
Neoplasia Press, Inc.
 patents

Years Active: 2003-2025

Loading Chart...
9 patents (USPTO):Explore Patents
1. 12428463 - Chimeric antigen receptors targeting abnormal glycobiology (2025-09-30),
2. 11760786 - Chimeric antigen receptors targeting abnormal glycobiology (2023-09-19),
3. 9289140 - Systems and methods for imaging changes in tissue (2016-03-22),
4. 8768431 - Systems and methods for tissue imaging (2014-07-01),
5. 8185186 - Systems and methods for tissue imaging (2012-05-22),
6. 7539938 - System and method for facilitating the pre-publication peer review process (2009-05-26),
7. 7378078 - Compositions and methods for detecting proteolytic activity (2008-05-27),
8. 7007232 - System and method for facilitating the pre-publication peer review process (2006-02-28),
9. 6567684 - Imaging system, computer, program product and method for detecting changes in rates of water diffusion in a tissue using magnetic resonance imaging (MRI) (2003-05-20),

Title: Alnawaz Rehemtulla: Innovator in Chimeric Antigen Receptors

Introduction

Alnawaz Rehemtulla is a prominent inventor based in Plymouth, MI (US). He has made significant contributions to the field of biotechnology, particularly in the development of chimeric antigen receptors (CAR) for cancer treatment. With a total of 9 patents, his work has the potential to revolutionize cancer therapies.

Latest Patents

One of his latest patents focuses on chimeric antigen receptors targeting abnormal glycobiology. The disclosure provides a CAR polypeptide that includes an antigen binding domain with an extracellular lectin. This lectin specifically binds to glycoproteins expressed on the surface of target cells. Additionally, the patent includes engineered lymphocytes that express the CAR polypeptide, a nucleic acid molecule encoding the CAR polypeptide, and methods for treating cancer.

Career Highlights

Throughout his career, Alnawaz has worked with notable institutions such as the University of Michigan and Neoplasia Press, Inc. His innovative research has garnered attention and respect within the scientific community.

Collaborations

Alnawaz has collaborated with esteemed colleagues, including Brian Dale Ross and Thomas L Chenevert. These partnerships have further enhanced his research and contributions to the field.

Conclusion

Alnawaz Rehemtulla's work in developing chimeric antigen receptors represents a significant advancement in cancer treatment. His innovative approach and dedication to research continue to inspire future developments in biotechnology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…